Decoding the autoantibody reactome science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.
Rogue antibodies are major culprits in severe cases of COVID-19, researchers report.
These autoantibodies target and react with a person’s tissues or organs similar to ones that cause autoimmune diseases such as lupus or rheumatoid arthritis. In COVID-19 cases they can attack healthy tissue in brain, blood vessels, platelets, liver, and the gastrointestinal tract, researchers report. The more autoantibodies detected, the greater the disease severity patients experience.
And the autoantibodies paradoxically also target and interfere with many immune system proteins that are designed to fend off infections, according to a new study.
The development of antibodies in response to the COVID-19 virus has been the great long-term hope for ending the pandemic, but it might not be so simple.
Golden Tickets winners Bolden Therapeutics and Seranova Bio will have access to a state-of-the-art lab facilities at LabCentral with mentorship and support from Biogen CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) and LabCentral today announced Bolden Therapeutics and Seranova Bio as the recipients of Biogen’s Golden Tickets, an initiative offering promising winning startups one year of lab space accompanied by continued mentorship from Biogen. LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. As a platinum-level sponsor of the program, Biogen demonstrates its ongoing commitment to innovation and support for the local biotech community by awarding Golden Tickets to two companies each year. This includes up to one year of the benefits of LabCentral’s shared infrastructure and services. “For people living with diseases that impact the central nervous